Bengaluru: AstraZeneca is reportedly in discussions with Summit Therapeutics to license an experimental lung cancer drug in a ...

Summit Therapeutics Inc. (NASDAQ: SMMT) is one of the best hot stocks to buy according to Wall Street analysts. On July 3, ...

European stocks closed lower on Friday amid concerns about U.S. tariffs, and on some disappointing regional economic data. With the July 9 deadline to strike ...

ASTRAZENECA is in talks with Summit Therapeutics to license an experimental lung-cancer drug under a deal worth as much as $15 billion, Bloomberg News reported on Thursday, citing people familiar with ...

The Business Research Company's Asthma and COPD Drugs Market 2025: Strategic Insights for Growth, Expansion, and Gaining Competitive Edge It will grow to $50.99 billion in 2029 at a compound annual ...

The pound was quoted down at USD1.3650 at midday on Friday in London, compared to USD1.3654 at the equities close on Thursday. The euro stood higher at USD1.778, against USD1.1762. Against the yen, ...

London has struggled for several years to attract big-name IPOs amid a dearth of liquidity and a less favourable regulatory climate, with reforms last year so far failing to arrest the decline.

Summit Therapeutics nears a $15B AstraZeneca deal for ivonescimab, targeting a $90B market. See more on the potential and ...

As part of this initiative, Invest UP — the state’s nodal investment promotion agency — is organising a series of global roadshows and strategic business engagements across the United States, Europe, ...

Starboard Value has gained a reputation for pushing for changes such as new CEOs and cost cuts by acquiring significant ...

It might be gearing up to pay billions of dollars to participate in a drug program currently in development. AstraZeneca ...

The company is betting that the alternative cytotoxic payload in its ADC can overcome resistance in patients who relapse on Enhertu.